PD-L1 (Programmed death ligand 1) • TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • CEACAM5 (CEA Cell Adhesion Molecule 5)

PTEN mutation

carboplatin • Zejula (niraparib) • cabazitaxel • cetrelimab (JNJ-63723283)

A Modular Trial of Androgen Signaling Inhibitor Combinations Testing a Risk-Adapted Strategy in Patients with Metastatic Castration-Resistant Prostate Cancer. (PubMed, Clin Cancer Res)

Adding ipilimumab to AAPA did not improve outcomes in men with androgen responsive mCRPC. Despite the addition of carboplatin+cabazitaxel, men in the Unsatisfactory group had shortened survivals. Adaptive designs can enrich for biologically and clinically relevant disease subgroups, to contribute to the development of marker-informed, risk-adapted therapy strategies in men with prostate cancer.

4 days ago

Journal • Metastases

PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • SPP1 (Secreted Phosphoprotein 1) • IGFBP2 (Insulin-like growth factor binding protein 2)

Yervoy (ipilimumab) • carboplatin • abiraterone acetate • prednisone • cabazitaxel • Erleada (apalutamide)

DynaMO: Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)

P2, N=196, Active, not recruiting, M.D. Anderson Cancer Center | Trial completion date: May 2025 --> Mar 2026 | Trial primary completion date: May 2025 --> Mar 2026

7 days ago

Trial completion date • Trial primary completion date • Metastases

AR (Androgen receptor)

Yervoy (ipilimumab) • carboplatin • abiraterone acetate • prednisone • cabazitaxel • Erleada (apalutamide)

Long-term outcomes of a randomized, open-label, phase II study comparing cabazitaxel versus paclitaxel as neoadjuvant treatment in patients with triple-negative or luminal B/HER2-negative breast cancer (GENEVIEVE). (PubMed, ESMO Open)

The significant differences in pCR rates observed in both treatment arms did not significantly impact long-term outcomes for patients treated with cabazitaxel versus paclitaxel in the GENEVIEVE trial.

7 days ago

P2 data • Journal

HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor)

HER-2 negative • ER positive + PGR positive • PGR positive

paclitaxel • cabazitaxel

Activity of Lutetium-177 Prostate-specific Membrane Antigen and Determinants of Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Previously Treated with Cabazitaxel: The PACAP Study. (PubMed, Eur Urol Oncol)

Lu-PSMA demonstrated a substantial PSA decline but limited rPFS after cabazitaxel in a real-life setting. Adverse baseline characteristics, baseline positron-emission tomography parameters, and quality of PSA response may help identify patients less likely to benefit from Lu-PSMA.

7 days ago

Journal • Metastases

ADCYAP1 (Adenylate Cyclase Activating Polypeptide 1)

docetaxel • cabazitaxel

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland (clinicaltrials.gov)

P=N/A, N=1, Completed, Pfizer | Trial completion date: Jun 2023 --> Apr 2024 | Trial primary completion date: Jun 2023 --> Apr 2024

9 days ago

Trial completion date • Trial primary completion date • HEOR • Real-world evidence • Real-world • Metastases

docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • cabazitaxel • Erleada (apalutamide) • triptorelin • goserelin acetate • Firmagon (degarelix) • Xofigo (radium Ra-223 dichloride) • leuprolide acetate for depot suspension

11d

Kinesin Facilitates Phenotypic Targeting of Therapeutic Resistance in Advanced Prostate Cancer. (PubMed, Mol Cancer Res)

Combinational targeting of kinesins (ispinesib) with cabazitaxel was more effective than single monotherapies in inducing cell death in resistant prostate tumors. Implications: Our findings are of translational significance in identifying kinesin as a novel target of cross-resistance, towards enhancing therapeutic vulnerability and improved clinical outcomes in patients with advanced prostate cancer.

11 days ago

Journal • Metastases

CDH1 (Cadherin 1) • SLCO1B3 (Solute carrier organic anion transporter family member 1B3) • VIM (Vimentin) • KIFC1 (Kinesin Family Member C1)

CDH1 expression • VIM expression • CDH1 overexpression

cabazitaxel • ispinesib (SB-715992)

16d

A Randomised Trial of Cabazitaxel, Docetaxel, Mitoxantrone or Satraplatin (CDMS) Plus Surgery for Prostate Cancer Patients Without Metastasis (clinicaltrials.gov)

P1, N=50, Recruiting, Shanghai Jiao Tong University School of Medicine | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2024 --> Dec 2026

16 days ago

Trial completion date • Trial primary completion date • Surgery

docetaxel • mitoxantrone • cabazitaxel • Orplatna (satraplatin)

24d

Substudy 01A: Safety and Efficacy of MK-5684-based Treatment Combinations or MK-5684 Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) (clinicaltrials.gov)

P1/2, N=220, Not yet recruiting, Merck Sharp & Dohme LLC

24 days ago

New P1/2 trial • Metastases

Lynparza (olaparib) • docetaxel • cabazitaxel • ODM-208

Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer (clinicaltrials.gov)

P1, N=20, Completed, Sidney Kimmel Cancer Center at Thomas Jefferson University | Active, not recruiting --> Completed

1 month ago

Trial completion • Metastases

bicalutamide • cabazitaxel

CABPOSTAAT: Docetaxel Versus Cabazitaxel Post Abiraterone or Enzalutamide (clinicaltrials.gov)

P2, N=214, Active, not recruiting, Centre hospitalier de l'Université de Montréal (CHUM) | Recruiting --> Active, not recruiting

1 month ago

Enrollment closed

docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • prednisone • cabazitaxel

Association between the apoptotic effect of Cabazitaxel and its pro-oxidant efficacy on the redox adaptation mechanisms in prostate cancer cells with different resistance phenotypes. (PubMed, Cancer Biol Ther)

Moreover, the cytotoxic and apoptotic effects of Cab were less on RWPE-1 cells compared to LNCaP but were closer to those on the more aggressive LNCaP-HPR and C4-2 cells, except for the changing pro-oxidant effect of Cab. Consequently, this study indicates the variable pro-oxidant effects of Cab on redox-sensitive proteins, which could be a target for improving Cab's apoptotic effect more in aggressive PC cells.

1 month ago

Journal

HIF1A (Hypoxia inducible factor 1, alpha subunit)

cabazitaxel

2ms

FOcal Radiation for Oligometastatic Castration-rEsistant Prostate Cancer (FORCE) (clinicaltrials.gov)

P2, N=13, Completed, University of Michigan Rogel Cancer Center | Active, not recruiting --> Completed | Trial completion date: Mar 2024 --> Jul 2023

2 months ago

Trial completion • Trial completion date • Metastases

docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • cabazitaxel

2ms

XmAb®20717 (Vudalimab) Alone or in Combination With Chemotherapy or Targeted Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)

P2, N=85, Recruiting, Xencor, Inc. | Trial completion date: Jun 2024 --> Sep 2025 | Trial primary completion date: Jun 2023 --> Mar 2025

2 months ago

Trial completion date • Trial primary completion date • Combination therapy • Tumor mutational burden • Metastases

TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • HRD (Homologous Recombination Deficiency)

TMB-H • MSI-H/dMMR

Lynparza (olaparib) • carboplatin • docetaxel • cabazitaxel • vudalimab (XmAb717)

2ms

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial (clinicaltrials.gov)

P1, N=2, Terminated, OHSU Knight Cancer Institute | Active, not recruiting --> Terminated; Low accrual

2 months ago

Trial termination

Keytruda (pembrolizumab) • Opdivo (nivolumab) • Avastin (bevacizumab) • Venclexta (venetoclax) • Lynparza (olaparib) • Mekinist (trametinib) • erlotinib • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • Tafinlar (dabrafenib) • carboplatin • Imfinzi (durvalumab) • sorafenib • Rozlytrek (entrectinib) • imatinib • Sutent (sunitinib) • everolimus • Nerlynx (neratinib) • Iclusig (ponatinib) • Kadcyla (ado-trastuzumab emtansine) • Cotellic (cobimetinib) • Lorbrena (lorlatinib) • Lenvima (lenvatinib) • bortezomib • doxorubicin hydrochloride • capecitabine • Verzenio (abemaciclib) • Xtandi (enzalutamide capsule) • Cabometyx (cabozantinib tablet) • albumin-bound paclitaxel • Stivarga (regorafenib) • abiraterone acetate • oxaliplatin • Aliqopa (copanlisib) • Vizimpro (dacomitinib) • Zydelig (idelalisib) • daunorubicin • Zolinza (vorinostat) • Idhifa (enasidenib) • Farydak (panobinostat) • Erivedge (vismodegib) • Nubeqa (darolutamide) • bicalutamide • leucovorin calcium • cabazitaxel • Vesanoid (tretinoin) • fluorouracil topical

2ms

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) (clinicaltrials.gov)

P1/2, N=30, Recruiting, M.D. Anderson Cancer Center | Not yet recruiting --> Recruiting

2 months ago

Enrollment open

TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1)

TP53 mutation • PTEN mutation • LDH elevation

carboplatin • cabazitaxel • Hepacid (pegargiminase)

2ms

Interplay of Ritonavir-Boosted Oral Cabazitaxel with the Organic Anion-Transporting Polypeptide (OATP) Uptake Transporters and Carboxylesterase 1 in Mice. (PubMed, Mol Pharm)

Furthermore, we observed the tight binding of cabazitaxel and its active metabolites, including docetaxel, to plasma carboxylesterase (Ces1c) in mice, which may complicate the interpretation of pharmacokinetic and pharmacodynamic mouse studies. Collectively, these results will help to further optimize (pre)clinical research into the safety and efficacy of orally applied cabazitaxel.

2 months ago

Preclinical • Journal

CES1 (Carboxylesterase 1)

docetaxel • cabazitaxel

2ms

CASCARA: Castration Sensitive Carboplatin, Cabazitaxel and Abiraterone (clinicaltrials.gov)

P2, N=22, Active, not recruiting, Masonic Cancer Center, University of Minnesota | Recruiting --> Active, not recruiting | N=61 --> 22 | Trial primary completion date: May 2025 --> Jun 2023

2 months ago

Enrollment closed • Enrollment change • Trial primary completion date • Metastases

carboplatin • abiraterone acetate • cabazitaxel

3ms

c15-148: Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer (clinicaltrials.gov)

P1/2, N=37, Active, not recruiting, OHSU Knight Cancer Institute | Trial completion date: Dec 2023 --> Jul 2024

3 months ago

Trial completion date • Metastases

Xtandi (enzalutamide capsule) • cabazitaxel

3ms

Testis CAB: Cabazitaxel as Salvage Treatment for Cisplatin-resistant Germ Cell Cancer (clinicaltrials.gov)

P2, N=14, Terminated, University Hospital, Akershus | N=29 --> 14 | Recruiting --> Terminated; Insufficient recruitment

3 months ago

Enrollment change • Trial termination

cisplatin • cabazitaxel

3ms

Exploiting epigenetic targets to overcome taxane resistance in prostate cancer. (PubMed, Cell Death Dis)

To uncover novel targets, we performed an epigenetic drug screen on taxane (docetaxel and cabazitaxel) resistant CR-PCa cells. RNA-seq analysis revealed that BRPF1 knockdown affects the genes enriched in mTORC1 and UPR signaling pathways, revealing potential mechanisms underlying its functional impact, which is further supported by the enhancement of taxane response through the combined inhibition of ABCB1 and mTOR pathways, providing evidence for the involvement of multiple BRPF1-regulated pathways. Beyond clinical attributes (Gleason score, tumor stage, therapy outcome, recurrence), metastatic PCa databases further supported the significance of BRPF1 in taxane resistance, as evidenced by its upregulation in taxane-exposed PCa patients.

3 months ago

Journal

ABCB1 (ATP Binding Cassette Subfamily B Member 1) • SIRT1 (Sirtuin 1)

docetaxel • cabazitaxel

3ms

Cetuximab decorated redox sensitive D-alpha-tocopheryl- polyethyleneglycol-1000-succinate based nanoparticles for cabazitaxel delivery: Formulation, lung targeting and enhanced anti-cancer effects. (PubMed, Int J Pharm)

In addition, the in-vitro cellular uptake investigation showed that CTX-TPGS-SS-CMN6-NPs accumulated significantly compared to pure CMN6, TPGS-CMN6-NPs, and TPGS-SS-CMN6-NPs in the A549 cells. Furthermore, the targeting efficiency of developed NPs were analysed by ultrasound/photoacoustic and IVIS imaging.

3 months ago

Journal

EGFR (Epidermal growth factor receptor)

Erbitux (cetuximab) • cabazitaxel

3ms

Ritonavir reverses resistance to docetaxel and cabazitaxel in prostate cancer cells with acquired resistance to docetaxel. (PubMed, Cancer Drug Resist)

Both parental and resistant cell lines were treated with the taxane drugs docetaxel and cabazitaxel in combination with the P-gp/CYP3A4 inhibitor ritonavir and the P-gp inhibitor elacridar. In a Caco-2 P-gp transporter assay, functional inhibition of P-gp-mediated transport of docetaxel with ritonavir was demonstrated. Our results demonstrate that ritonavir restores sensitivity to both docetaxel and cabazitaxel in docetaxel-resistant cell lines, most likely by inhibiting P-gp-mediated drug efflux.

3 months ago

Preclinical • Journal

ABCB1 (ATP Binding Cassette Subfamily B Member 1)

docetaxel • cabazitaxel • elacridar (GF120918) • ritonavir

3ms

Intravesical Cabazitaxel, Gemcitabine, and Cisplatin (CGC) in the Treatment Urothelial Carcinoma of the Bladder (clinicaltrials.gov)

P1/2, N=51, Active, not recruiting, Guarionex J. Decastro | Recruiting --> Active, not recruiting

3 months ago

Enrollment closed

cisplatin • gemcitabine • cabazitaxel

3ms

The Efficacy and Safety of Polyethylene Glycol Cholesterol- and Tocopherol Polyethylene Glycol 1000 Succinate-Modified Transforming Growth Factor β1 Small Interfering RNA Lipid Nanoparticles in the Treatment of Paclitaxel-Resistant Non-Small-Cell Lung Cancer. (PubMed, Pharmaceutics)

The histopathological results showed that the three kinds of LNPs have a certain toxicity but are relatively safe compared to common forms of chemotherapy such as cabazitaxel. TGFβ1 siRNA LNPs modified with CE1.5, CE2.5, and TPGS2.5 can inhibit TGFβ1 mRNA and protein expression in A549/T cells in vitro and can accumulate and play a role in the tumor tissue of nude mice, features that can be exploited for treating paclitaxel-resistant lung adenocarcinoma.

3 months ago

Journal

TGFB1 (Transforming Growth Factor Beta 1)

paclitaxel • cabazitaxel

3ms

Combined Cabazitaxel and Carboplatin Treatment of Metastatic Castration Resistant Prostate Cancer Patients, With Innate or Acquired Resistance to Cabazitaxel Monotherapy. (PubMed, Clin Genitourin Cancer)

In this study we showed that patients with PSA progression during cabazitaxel monotherapy could benefit from the addition of carboplatin to cabazitaxel, while prospective identification of these patients remains a clinical challenge.

3 months ago

Preclinical • Journal • BRCA Biomarker • Metastases

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • PTEN (Phosphatase and tensin homolog) • ATM (ATM serine/threonine kinase) • RB1 (RB Transcriptional Corepressor 1) • BRCA (Breast cancer early onset)

TP53 mutation • BRCA2 mutation • BRCA1 mutation • ATM mutation • PTEN mutation • RB1 mutation • BRCA mutation • BRCA2 mutation + ATM mutation

carboplatin • cabazitaxel

4ms

A Study of Nivolumab Plus Ipilimumab, Ipilimumab Alone, or Cabazitaxel in Men With Metastatic Castration-Resistant Prostate Cancer (CheckMate 650) (clinicaltrials.gov)

P2, N=351, Active, not recruiting, Bristol-Myers Squibb | Trial completion date: Oct 2026 --> May 2024

4 months ago

Trial completion date • Metastases

Opdivo (nivolumab) • Yervoy (ipilimumab) • cabazitaxel

4ms

L-type amino acid transporter 1 inhibitor JPH203 prevents the growth of cabazitaxel-resistant prostate cancer by inhibiting cyclin-dependent kinase activity. (PubMed, Cancer Sci)

Moreover, JPH203 inhibited the proliferation of cabazitaxel-resistant cells in vivo. Taken together, the present study results suggest that LAT1 might be a valuable therapeutic target in cabazitaxel-resistant prostate cancer.

4 months ago

Journal

SLC7A5 (Solute Carrier Family 7 Member 5)

cabazitaxel • nanvuranlat (JPH203)

4ms

Quality by design fostered fabrication of cabazitaxel loaded pH-responsive Improved nanotherapeutics against prostate cancer. (PubMed, Colloids Surf B Biointerfaces)

Substantial reduction in the diameter of 3D-Tumoroid and enhanced cell proliferation inhibition indicated the efficacy of CBZ NP in PCa. Thus, we conclude that CBZ NP could be a promising Nanotherapeutic approach for PCa.

4 months ago

Journal • IO biomarker

BCL2 (B-cell CLL/lymphoma 2) • CASP1 (Caspase 1)

cabazitaxel

4ms

LuCAB: Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer (clinicaltrials.gov)

P1/2, N=44, Recruiting, Peter MacCallum Cancer Centre, Australia

4 months ago

Trial completion date • Combination therapy • Metastases

AR (Androgen receptor)

docetaxel • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

5ms

MK-5684 (ODM-208), a CYP11A1 inhibitor, in patients with metastatic castration-resistant prostate cancer (mCRPC) with and without AR-LBD mutations: CYPIDES phase 2 results. (ASCO-GU 2024)

53% and 33.8% of patients had previously received both abiraterone and enzalutamide, and 63.6% and 55.9% patients had received cabazitaxel in AR-LBD mutation positive and negative groups respectively. Administration of MK-5684 to heavily pre-treated mCRPC patients showed promising antitumor activity. PSA50 responses were most frequent among patients harboring activating AR-LBD mutations. Clinical trial information: NCT03436485.

5 months ago

P2 data • Clinical • Metastases

AR positive • AR mutation

Guardant360® CDx

Xtandi (enzalutamide capsule) • abiraterone acetate • cabazitaxel • ODM-208

5ms

First-in-human phase 1 study of CC-94676, a first-in-class androgen receptor (AR) ligand-directed degrader (LDD), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC). (ASCO-GU 2024)

Pts with mCRPC who progressed on androgen deprivation therapy, ≥ 1 second generation hormonal therapy (eg, enzalutamide [enza], abiraterone [abi], darolutamide, and apalutamide) and taxane chemotherapy (chemo) (unless refused or not indicated) were enrolled to evaluate the safety, tolerability, PK/PD, and preliminary efficacy of CC-94676... As of Aug 21, 2023, 95 pts received CC-94676 (median age 71 yrs) with a median of 5 (range 2–12) prior therapies, including enza (80%), abi (72%), both enza & abi (56%), and chemo (56%) (docetaxel 55%; cabazitaxel 20%)... CC-94676 is well tolerated with a manageable safety profile. CC-94676 shows promising and prolonged clinical activity in heavily pretreated mCRPC pts who progressed on abi, enza, and chemo with activity seen in pts with tumors expressing WT and mutant ARs. Selection of the recommended phase 2 dose is ongoing.

5 months ago

Clinical • P1 data • Metastases

AR (Androgen receptor)

AR wild-type

docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • Nubeqa (darolutamide) • cabazitaxel • Erleada (apalutamide)

5ms

Overall survival with [Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. (PubMed, Lancet Oncol)

These results support the use of [Lu]Lu-PSMA-617 as an alternative to cabazitaxel for PSMA-positive metastatic castration-resistant prostate cancer progressing after docetaxel. We did not find evidence that overall survival differed between the randomised groups. Median overall survival was shorter for men who were excluded because of low PSMA expression or 2-[F]FDG-discordant disease.

5 months ago

P2 data • Journal • Metastases

FOLH1 (Folate hydrolase 1)

FOLH1 expression • FOLH1 positive

docetaxel • cabazitaxel • Pluvicto (lutetium Lu 177 vipivotide tetraxetan)

6ms

EGFR Targeted Redox Sensitive Chitosan Nanoparticles of Cabazitaxel: Dual-Targeted Cancer Therapy, Lung Distribution, and Targeting Studies by Photoacoustic and Optical Imaging. (PubMed, Biomacromolecules)

Dual-receptor targeting redox-sensitive nanoparticles of CZT (F-CTX-CZT-CS-SH-NPs) were developed by a combination of pre- and postconjugation techniques by incorporating synthesized chitosan-folate (F) and TPGS-SH during nanoparticle synthesis and further postconjugated with cetuximab (CTX) for epidermal growth factor receptor (EGFR) targeting. Furthermore, F-CTX-CZT-CS-SH-NPs demonstrated improved anticancer activity in the benzo(a)pyrene lung cancer model with a higher survival rate. Due to the synergistic combination of enhanced permeability and retention (EPR) effect of small-sized nanoparticles, the innovative and redox sensitive TPGS-SH moiety and the dual folate and EGFR mediated augmented endocytosis have all together significantly enhanced their biodistribution and targeting exclusively to the lung which is evident from their ultrasound/photoacoustic and in vivo imaging system (IVIS) studies.

6 months ago

Journal

EGFR (Epidermal growth factor receptor)

Erbitux (cetuximab) • cabazitaxel

6ms

Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer. (PubMed, J Clin Oncol)

AAP + C was safe with improved rPFS, OS duration, and a higher proportion of PSA declines. This suggests that AAP + C given earlier rather than sequentially may benefit some men. Further work is needed to identify this population.

6 months ago

P2 data • Journal • Metastases

RB1 (RB Transcriptional Corepressor 1)

docetaxel • abiraterone acetate • cabazitaxel

6ms

Prevalence of HRR gene mutations in patients with metastatic prostate cancer (mPC): results from a single center in Mexico (EMUC 2023)

70% received docetaxel, 84% novel antiandrogens, 28% cabazitaxel, 16% other treatments. Presence and type of alterations may vary within populations even in same regions. Further study is warranted.

6 months ago

Clinical • BRCA Biomarker • Metastases

BRCA1 (Breast cancer 1, early onset) • BRCA2 (Breast cancer 2, early onset) • ATM (ATM serine/threonine kinase) • HRD (Homologous Recombination Deficiency) • CHEK2 (Checkpoint kinase 2)

BRCA2 mutation • BRCA1 mutation • ATM mutation

AmoyDx® HANDLE HRR NGS Panel

docetaxel • cabazitaxel

6ms

Real World Evidence Study on Metastatic Prostate Cancer in the Pirkanmaa Hospital District in Finland (clinicaltrials.gov)

P=N/A, N=1, Completed, Pfizer | Recruiting --> Completed | Trial completion date: Nov 2023 --> Jun 2023 | Trial primary completion date: Nov 2023 --> Jun 2023

6 months ago

Trial completion • Trial completion date • Trial primary completion date • HEOR • Real-world evidence • Real-world • Metastases

6ms

Pathway-driven analysis of synthetic lethal interactions in cancer using perturbation screens. (PubMed, Life Sci Alliance)

In addition, we proposed several FDA-approved cancer-targeted drugs for various cancer types through PRISM drug screens, such as cabazitaxel for VHL-mutated kidney cancer and alectinib for lung cancer with NRAS or KRAS mutations. Leveraging pathway information can enhance the concordance of shRNA and CRISPR screens and provide clinically relevant findings such as the potential efficacy of dasatinib, an inhibitor of SRC, for colorectal cancer patients with mutations in the WNT signaling pathway. These analyses revealed that taking signaling pathway information into account results in the identification of more promising SL interactions.

6 months ago

Journal • Synthetic lethality

KRAS (KRAS proto-oncogene GTPase) • TP53 (Tumor protein P53) • NRAS (Neuroblastoma RAS viral oncogene homolog) • CCND1 (Cyclin D1) • CCNE1 (Cyclin E1) • VHL (von Hippel-Lindau tumor suppressor) • TCF7L2 (Transcription Factor 7 Like 2) • METTL1 (Methyltransferase 1, TRNA Methylguanosine)

KRAS mutation • NRAS mutation • VHL mutation

dasatinib • Alecensa (alectinib) • cabazitaxel

6ms

CHAMP: A Study of Chemoimmunotherapy for the Treatment of Men With Neuroendocrine or Aggressive Variant Metastatic Prostate Cancer (clinicaltrials.gov)

P2, N=43, Recruiting, Andrew J. Armstrong, MD | Active, not recruiting --> Recruiting

6 months ago

Enrollment open • IO biomarker • Metastases

TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1) • CEACAM5 (CEA Cell Adhesion Molecule 5) • SYP (Synaptophysin) • CHGA (Chromogranin A)

LDH elevation

Opdivo (nivolumab) • Yervoy (ipilimumab) • carboplatin • cabazitaxel

6ms

Biweekly vs Triweekly Cabazitaxel in Older Patients With Metastatic Castration-Resistant Prostate Cancer: The CABASTY Phase 3 Randomized Clinical Trial. (PubMed, JAMA Oncol)

All patients had received docetaxel and at least 1 novel androgen receptor-targeted agent. The findings suggest that biweekly CBZ16 regimen should be offered to patients 65 years or older with mCRPC for whom the standard regimen is unsuitable. ClinicalTrials.gov Identifier: NCT02961257.

6 months ago

Clinical • P3 data • Journal • Metastases

AR (Androgen receptor)

docetaxel • cabazitaxel

6ms

Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial. (PubMed, ESMO Open)

Plasma AR-CN correlates with survival not only at baseline (before first treatment), but also in the assessments before the following lines. Interestingly, AR-CN status may change from normal to gain across subsequent treatments in a significant number of cases, identifying a group of patients with intermediate outcomes. Longitudinal assessment of AR-CN status could represent a promising method to capture mCRPC intrinsic heterogeneity and to improve clinical management.

6 months ago

Journal

AR (Androgen receptor)

docetaxel • Xtandi (enzalutamide capsule) • abiraterone acetate • cabazitaxel

7ms

Phase I/II Study of PEGylated Arginine Deiminase (ADI-PEG20) With Carboplatin and Cabazitaxel in Men With Aggressive Variant Prostate Cancers (AVPC) (clinicaltrials.gov)

P1/2, N=30, Not yet recruiting, M.D. Anderson Cancer Center

7 months ago

New P1/2 trial

TP53 (Tumor protein P53) • PTEN (Phosphatase and tensin homolog) • RB1 (RB Transcriptional Corepressor 1)

TP53 mutation • PTEN mutation • LDH elevation

carboplatin • cabazitaxel • Hepacid (pegargiminase)